Eggoz 
Dealstreet

VERTICES PARTNERS, Saraf and Partners act on Eggoz ₹167 crore Series C fundraise

The fundraise was led by Gaja Gapital.

Bar & Bench

Eggoz (Nupa Technologies Private Limited) has raised ₹167 crore from a Series C fundraise led by Gaja Capital. Other key existing investors, IvyCap Ventures, Rebright Partners, Avaana Capital, Merisis Opportunities Fund, Nabventures, Blue Dot Capital and Artek Chemicals, have also participated in the round.

VERTICES PARTNERS advised Eggoz on this fundraise.

The transaction team was led by Vikrant Anand (Partner), and included Shagun Rathi Mittal (Senior Associate), and Associates - Hemant Srivastava and Anna Liji Thomas.

Founder and Managing Partner Vinayak Burman provided strategic inputs

Vikrant Anand, Vinayak Burman

Saraf and Partners represented lead investor Gaja Capital on this fundraise. The Firm advised Gaja across the entire transaction lifecycle, including legal due diligence, negotiation of complex multi-party documentation, regulatory advisory, and closing assistance.

The transaction team consisted of Vivek Pareek (Partner) and Sanika Gadgil (Associate).

Vivek Pareek

Founded in 2017 by Abhishek Negi, Uttam Kumar, and Aditya Singh, Eggoz provides high-quality, farm-fresh eggs. The company prides itself on offering one-day fresh eggs that are free from chemicals and antibiotics, sourced from hens that are fed a 100% herbal diet. Eggoz aims to make a meaningful impact on protein consumption while supporting rural egg farmers, ensuring that their products contribute positively to both health and community welfare.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

How the UK High Court held Nirav Modi liable to pay ₹100 crore personal guarantee to Bank of India

The search tax: Indian litigation's hidden cost

Arbitrating fraud: The serious fraud exception and its shrinking boundaries

Justice Prathiba M Singh becomes first Indian judge in global IP Hall of Fame

Shardul Amarchand Mangaldas advises Krishna Institute of Medical Sciences on ₹1,500 crore QIP

SCROLL FOR NEXT